Formation Bio

We are an AI-native pharma company founded in 2013 to make drug development radically more efficient. We acquire clinical-stage drugs from pharmaceutical and biotech companies and universities, developing them with our proprietary technology platforms. Our platforms optimize clinical trial design, speed up completion, and improve data quality.

Our goal is to accelerate patient access to new treatments by removing bottlenecks and increasing the value of each program. We were honored with the 2025 CNBC Disruptor 50, 2025 Fierce 15, and 2024 Endpoints 11 awards. Our work spans clinical pharmacology, medical writing, trial execution, medical affairs, engineering, data science (including medical imaging and EHR data), and GMP quality assurance.

Our mission is to bring new treatments to patients faster and more efficiently. We operate as a tech-driven, AI-native pharma company, focused on changing how drug development is conducted.

We emphasize radical efficiency throughout the drug development lifecycle, without compromising quality or safety. We do this by integrating process improvement with our proprietary technology, AI advancements, and talent. We believe in combining expertise from technology and pharmaceuticals to scale and transform the drug development industry.

We have 51-200 employees. Our multidisciplinary team brings together expertise from drug selection, drug development, and technology.

We foster a fast-paced, tech-enabled drug development environment that prioritizes rapid, high-quality decision-making. We aim to build capable teams that can scale with our portfolio, championing a culture of quality, transparency, and continuous improvement. Our team consists of tech and pharma experts committed to accelerating patient access to new treatments.

We offer equity participation, comprehensive benefits packages, and generous perks. We provide hybrid work flexibility, with some roles requiring 1-3 days in the office, and offer location flexibility for certain regions or hubs.